In a legal proceeding that has captured the attention of mass tort litigators nationwide, Judge Joshua Roberts of the Philadelphia Court of Common Pleas declined to recuse himself from overseeing cases related to Zantac, the popular heartburn medication. This decision came after a motion filed by the plaintiffs’ counsel, which Judge Roberts suggested may have been intended as a criticism of his overall management of the mass torts program. The judge addressed these concerns directly in a footnote of his opinion, remarking, “A more cynical view of the circumstances is that plaintiffs’ counsel used the motion as a broadside against my oversight of the entire mass torts program.”
To explore the full context and implications of Judge Roberts’ decision, legal professionals can access the details of the case as reported by The Legal Intelligencer.